Featured Trial:
Lung Cancer Treatment

Featured Trial:
Colorectal Cancer Treatment

Featured Trial:
Melanoma Imaging

Featured Trial:
Head and Neck Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

October 11, 2024

Categories

News Stories

Journal of Clinical Oncology publishes RTOG 1106/ACRIN 6697 results: Midtreatment PET-adapted radiotherapy dose escalation fails to improve outcomes for lung cancer patients

October 11, 2024

Categories

News Stories

Mid-treatment PET-adapted radiotherapy dose escalation fails to improve outcomes for lung cancer patients: Results of NRG-RTOG1106/ECOG-ACRIN 6697

October 10, 2024

Categories

News Stories

Women in medicine month: celebrating women advancing radiology (mentions TMIST investigator Rita Freimanis, MD)

September 26, 2024

Categories

The Fall 2024 advocacy blog Considering Clinical Trials is now available

September 20, 2024

Categories

Announcements

The September 2024 News from ECOG-ACRIN blog is now available

September 18, 2024

Categories

Press Releases

Press Release: Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

September 10, 2024

Categories

Press Releases

Press Release: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Posts

ECOG-ACRIN Cancer Research Group Follow 7,825 6,299

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

1h 1908210545183932478

The MM1OA-EA02 clinical study is testing a new treatment approach for patients with #AcuteMyeloidLeukemia who are age 60 or older. Learn more: https://bit.ly/mm1oa-ea02-study #AML #leukemia

Reply on Twitter 1908210545183932478 Retweet on Twitter 1908210545183932478 0 Like on Twitter 1908210545183932478 0 Twitter 1908210545183932478

; ECOG-ACRIN Cancer Research Group @eaonc ·

2h 1908194514549772624

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial

Reply on Twitter 1908194514549772624 Retweet on Twitter 1908194514549772624 0 Like on Twitter 1908194514549772624 0 Twitter 1908194514549772624

; ECOG-ACRIN Cancer Research Group @eaonc ·

3 Apr 1907861646300561634

Could #greentea catechins help prevent the progression of #prostatecancer in men on active surveillance? #Clinicaltrial EA8184, led by Dr. Nagi Kumar of @MoffittNews, aims to find out. Learn more: http://bit.ly/ea8184-trial #pcsm cc: @jpowsang

Reply on Twitter 1907861646300561634 Retweet on Twitter 1907861646300561634 0 Like on Twitter 1907861646300561634 2 Twitter 1907861646300561634

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).